Leukemias related to treatment with DNA topoisomerase II inhibitors

Medical and Pediatric Oncology
C A Felix

Abstract

The epipodophyllotoxins etoposide and teniposide and other DNA topoisomerase II inhibitors including anthracyclines and dactinomycin are highly efficacious anticancer drugs. All are associated with a distinct form of leukemia characterized by chromosomal translocations as a treatment complication. Most of the translocations disrupt a breakpoint cluster region (bcr) of the MLL gene at chromosome band 11q23. Other characteristic translocations also may occur. The normal function of the nuclear enzyme DNA topoisomerase II is to catalyze changes in DNA topology between relaxed and supercoiled states by transiently cleaving and re-ligating both strands of the double helix. Anticancer drugs that are DNA topoisomerase II inhibitors are cytotoxic because they form complexes with DNA and DNA topoisomerase II. The complexes decrease the re-ligation rate, disrupt the cleavage-re-ligation equilibrium, and have a net effect of increasing cleavage. The increased cleavage damages the DNA and leads to chromosomal breakage. Cells with irreparable DNA damage die by apoptosis. The association of DNA topoisomerase II inhibitors with leukemia suggests that the drug-induced, DNA topoisomerase II-mediated chromosomal breakage may be relevant to trans...Continue Reading

References

Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P HungerM P Link
Aug 8, 1992·Lancet·A G ZeimetO Dapunt
Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L DetourmigniesF Bauters
Sep 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Pedersen-BjergaardP Dombernowsky
Nov 30, 1991·Lancet·M M Hawkins
Dec 12, 1991·The New England Journal of Medicine·C H PuiJ T Sandlund
Aug 18, 1990·Lancet·C H PuiC B Pratt
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B K SinhaY Pommier
Jun 15, 1989·Cancer·P FenauxF Bauters
Jul 20, 1989·The New England Journal of Medicine·C H PuiS B Murphy
Dec 7, 1988·Journal of the National Cancer Institute·J M van MaanenH M Pinedo
Oct 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H J WehD K Hossfeld
Jan 1, 1985·Medical and Pediatric Oncology·L M Secker-WalkerA Todd
Jan 1, 1983·American Journal of Clinical Pathology·V L RoseJ L Murray
May 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L Y ChakR S Cox
Jan 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BoshoffJ Ong
Jan 6, 1993·Journal of the National Cancer Institute·C R NicholsL H Einhorn
Jan 6, 1993·Journal of the National Cancer Institute·D F BajorinG J Bosl
Aug 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·P H DomerS J Korsmeyer
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·F M Muggia
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·G K RiveraW M Crist
Jan 1, 1994·Medical and Pediatric Oncology·R M EgelerM E Nesbit
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B QuesnelJ L Harousseau
Sep 1, 1993·Chemical Research in Toxicology·A H Corbett, N Osheroff
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·Q MaA M Buchberg
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G K RiveraW M Crist

❮ Previous
Next ❯

Citations

Feb 7, 2002·Pharmacoepidemiology and Drug Safety
Jan 6, 2004·International Journal of Hematology·Mariko EguchiMel Greaves
Feb 3, 2009·Cancer Chemotherapy and Pharmacology·Sabry M AttiaMohammed M Al-Harbi
Jan 1, 2005·Journal of Cancer Research and Clinical Oncology·J WiereckyC Bokemeyer
Dec 31, 2009·Apoptosis : an International Journal on Programmed Cell Death·Ilona SchonnDorothee C Dartsch
Aug 8, 2008·Bulletin of Experimental Biology and Medicine·T I FominaE A Timina
Nov 10, 2007·Current Oncology Reports·Dan S Gombos, And Patricia Chevez-Barrios
Jan 19, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Melanie Joannides, David Grimwade
Mar 26, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G KleinP Kaatsch
Jan 28, 2003·DNA Repair·Kyungjae Myung, Richard D Kolodner
Apr 27, 2007·Biochemistry·Omari J Bandele, Neil Osheroff
Feb 26, 2008·Chemical Research in Toxicology·Omari J Bandele, Neil Osheroff
May 1, 2013·Leukemia·C MeyerR Marschalek
Jun 8, 2012·Nature Medicine·Rushdia Z YusufDavid T Scadden
Apr 15, 2005·The New England Journal of Medicine·Anita R MistryDavid Grimwade
Nov 6, 2010·Japanese Journal of Clinical Oncology·Yuko ArakiAtsushi Makimoto
Jul 31, 2003·Nucleic Acids Research·Michelle SabourinNeil Osheroff
Feb 19, 2005·Nucleic Acids Research·E L BaldwinN Osheroff
Dec 2, 2008·Nucleic Acids Research·Joseph E Deweese, Neil Osheroff
Sep 22, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Yan LiJin Ren
Jun 24, 2006·Journal of Pediatric Hematology/oncology·Kudret CağlarMünevver Büyükpamukçu
Jun 10, 2008·Current Opinion in Hematology·Jac A NickoloffRobert Hromas
Jul 19, 2013·The British Journal of Ophthalmology·Annette KünkeleJohannes H Schulte
Dec 17, 2005·The Journal of Clinical Investigation·Shinichiro NakadaShuki Mizutani
Mar 3, 2010·BMC Genomics·Albert G Tsai, Michael R Lieber
Dec 1, 2009·Cases Journal·Elisa Dorantes-AcostaAurora Medina-Sanson
May 25, 2006·International Journal of Hematology·Naoko TakeiToshiro Nagasawa
Apr 13, 2006·Paediatric Drugs·Robert E GoldsbyArthur R Ablin
Apr 4, 2002·Proceedings of the National Academy of Sciences of the United States of America·Leslie J RaffiniCarolyn A Felix
Jun 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anna M AzarovaLeroy F Liu
Apr 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hai XiaoLeroy F Liu
Nov 10, 2006·Proceedings of the National Academy of Sciences of the United States of America·Michael M Vilenchik, Alfred G Knudson
May 3, 2014·Critical Reviews in Oncology/hematology·Rebecca L Wright, Andrew T M Vaughan
Feb 14, 2013·Chemical Research in Toxicology·Birandra K SinhaRonald P Mason
Mar 19, 2011·Pediatric Hematology and Oncology·Ali Varan, Rejin Kebudi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthracycline Sensitivity & Chromatin (Keystone)

Anthracyclines are used in the treatment of cancer and work by inhibiting topoisomerase II (TOP2). Recent evidence suggests that because DNA accessibility is crucial for TOP2 binding, chromatin regulatory genes should predict anthracycline response. Find the latest research on anthracycline sensitivity and chromatin regulators in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis